New Products for Molecular and Companion Diagnostics Drive Growth
Rayno Life Science Big Winners-ALR, CSII, ILMN,TMO
A diversified life science portfolio must include clinical diagnostics and tools stocks because of the synergies between therapy and diagnostics. Breakthroughs in molecular diagnostics for personalized medicine, genetic testing and infectious diseases are driving new product cycles for timely, more cost effective therapies. Sequencing tools from companies like Illumina (ILMN) and Life Technologies (LIFE) pending merger with ThermoFisher (TMO) , are entering an explosive growth phase leading the way for new clinical applications in a new age of molecular medicine.
Here is a brief review of our current focus stocks. Click on the link below for a more detailed review of picks.
Rayno Diagnostics and Tools Stocks-Performance YTD
Cardiovascular Sciences (CSII $33) Up 163% YTD Cardiovascular medTech
Illumina (ILMN $110.38) up 99% YTD NEW HIGH
Alere (ALR $36) up 94.4% YTD Near 52 Week High
ThermoFisher (TMO $110.7) up 73.5% YTD NEW HIGH
Quidel ( QDEL $27.4) up 47% YTD
Cepheid ($46) up 37.2% YTD
Qiagen (QGEN $23.2) up 28% YTD
Exact Sciences (EXAS $12.24) up 15.6% YTD
Genomic Health (GHDX $29.85) up 9.6% YTD
Abaxis (ABAX $39.61) up 6.8% YTD
Neogen (NEOG $45.75) up 1% YTD
Sequenom (SQNM $2.30) down 51% YTD
Response Genetics (RGDX $1.16) down 17% YTD
New Picks-2013 Growth, Value and Turnaround Plays
See background from November 14 post.
NanoString (NSTG $16.4) Buy at $12 Up 25%
Meridian (VIVO $26.35) Value Play at $25.5, pays 2.9% dividend.
Hologic (HOLX $22.36) Restructuring play at $21.60.
Luminex (LMNX $19.17) Turnaround candidate at $19.
NanoSphere (NSPH $2.12) Turnaround and re-start candidate.
Vermillion (VRML $2.51) Turnaround and restructuring candidate.